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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, and in 
spite of intense efforts there are limited therapeutic options for patients with PDAC. 
PDACs harbor a high frequency of Kras mutations and other driver mutations that lead 
to altered signaling pathways and contribute to therapeutic resistance. Importantly, 
constitutive activation of nuclear factor κB (NF-κB) is frequently observed in PDAC. 
An increasing body of evidence suggests that both classical and non-classical NF-κB 
pathways play a crucial role in PDAC development and progression. In this review, we 
update the most recent advances regarding different aspects of NF-κB involvement in 
PDAC development and progression, emphasizing its potential as a therapeutic target 
and the need to discover pathway-specific cytosolic NF-κB regulators which could be 
used to design novel therapeutic strategies for PDAC.
INTRODUCTION
NF-κB superfamily and its signaling pathways
The nuclear factor κB (NF-κB) transcription factor 
was discovered when it was observed that it binds to 
the enhancer element of the immunoglobulin κ light-
chain of activated B cells [1]. NF-κB plays critical roles 
in inflammation, cell proliferation and differentiation, 
immune response and cancer [2]. There are five proteins 
in the mammalian NF-κB family: RelA (p65), RelB, 
c-Rel, p50/p105 and p52/p100. They all share a Rel 
homology domain (RHD) in their N-terminus, which 
results in their classification as NF-κB/Rel proteins. The 
RHD is essential for dimerization as well as binding to 
κB cognate DNA elements. NF-κB activity is primarily 
regulated by interaction with a family of inhibitors called 
IκBs (inhibitor of κB) proteins. IκB proteins mask the 
nuclear localization signals (NLS) of NF-κB proteins and 
keep them sequestered in a latent, inactive complex in the 
cytoplasm.
There are two different pathways involving 
NF-κB: the classical (or canonical) and non-classical 
(or non-canonical) pathways. In the classical NF-κB 
activation pathway, upon receiving extracellular signals 
such as stress, cytokines, free radicals, or radiation, the 
IκB kinase (IKK) phosphorylates IκB [3], which then 
signals the ubiquitination and degradation of IκB by 
the proteasome system. The p65/p50 heterodimer of 
NF-κB is then released and can rapidly enter the nucleus 
to ‘turn on’ the expression of a variety of κB-dependent 
genes. By contrast, the non-classical pathway is mediated 
via p100/RelB complexes that are normally inactive in 
the cytoplasm. Signaling through a subset of receptors, 
such as LTβR (lymphotoxin β receptor) and CD40, 
activates the NF-κB-inducing kinase (NIK), which in turn 
activates IKKα complexes that phosphorylate C-terminal 
residues in p100. Phosphorylation of p100 leads to its 
ubiquitination and proteasomal processing to p52, leading 
to the formation of p52/RelB complexes that translocate to 
the nucleus and induce target gene expression.
Correlation between NF-κB with different types 
of cancer
Constitutive NF-κB activation has been noted 
in 95% of all cancers [4–6]. Oncogenic roles of 
NF-κB include promotion of cell proliferation, control 
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of apoptosis, and stimulation of angiogenesis, invasion/
metastasis in cancer cells.
Numerous studies have now documented the role 
of NF-κB in the development of solid malignancies. For 
instance, NF-κB has been shown to be involved in the 
development of breast cancer. Thus, constitutive NF-κB 
DNA-binding activity is seen in mammary carcinoma 
cell lines and primary breast cancer cells of human and 
rodent origin [7]. Furthermore, NF-κB has been shown 
to function as a key link between inflammatory bowel 
disease (IBD) and colorectal cancer (CRC) by regulating 
inflammatory responses and providing a barrier against 
extrinsic hazard. Studies with azoxymethane (AOM)/
dextran sodium sulfate (DSS) mouse models of colitis-
associated colon cancer (CAC) and animal models 
carrying a conditional disruption of IKKβ have been 
used to show that IKKβ-driven NF-κB activation within 
intestinal epithelial cells (IECs) is essential for CRC 
development [8–10]. Another example is the involvement 
of NF-κB in melanoma, the most aggressive form of 
skin carcinoma [11]. It has been demonstrated that 
upregulation of the NF-κB levels is responsible for both 
the development and metastasis of melanoma. In addition 
to solid tumors, since NF-κB plays a very important 
role in immune cell function, hyperactive NF-κB is also 
frequently associated with the development of leukemia 
and lymphoma [12].
Role of NF-κB in pancreatic ductal 
adenocarcinoma (PDAC)
It is generally considered that oncogenic Kras is 
the initiating molecular alteration in PDAC [13–15]. 
Its importance in PDAC became clearly evident with 
the generation of the first genetically engineered mouse 
model (GEMM) of PDAC that truly recapitulated the 
histological features seen in humans. Thus, KC (stands 
for Kras;Pdx1-Cre recombinase) mouse carries an 
oncogenic Kras (KrasG12D) allele that has been knocked-
in within its own locus and silenced by the insertion 
of an upstream LoxP-Stop-LoxP (LSL) element [16]. 
Oncogenic Kras transcription is thus controlled by its 
endogenous promoter, and the transcript is expressed 
in early pancreatic progenitors after LSL excision by 
a pancreas-specific Cre recombinase such as Pdx-1. 
KC mice develop low grade pancreatic intra-epithelial 
neoplasia (PanIN) and exhibit areas of acinar to ductal 
metaplasia (ADM) by 2 months of age [16]. By age 8 
to 12 months, KC mice develop PDAC at moderate 
penetrance [16]. PanIN is a crucial feature of PDAC 
initiation in humans and GEMMs, and PanIN progression 
to PDAC is accelerated by loss of tumor suppressor 
genes such as p53, Cdkn2A (cyclin-dependent kinase 
inhibitor 2A), Smad4 (mothers against decapentaplegic 
homolog 4), Pten (phosphatase and tensin homolog), or 
Rb (retinoblastoma protein) [17–21].
PDAC exhibits marked resistance to chemotherapy 
and radiotherapy, a propensity to metastasize, and a 
dismal 5-year survival rate of 6% [22–24]. Given the 
role of NF-κB in different cancer types, and the fact that 
NF-κB transcriptional factors are constitutively activated 
in the majority of PDACs, it is likely that NF-κB-driven 
pathways are involved in the regulation of numerous 
aspects of PDAC development and progression.
Links between Kras mutation and NF-κB 
signaling in PDAC
NF-κB is known to be constitutively activated in 
most PDAC patients [25]. Instances of NF-κB pathway 
interacting with concurrent signaling pathways have been 
recently documented, which might contribute towards 
the PDAC etiology. For instance, it was shown that the 
KrasG12D mutation seen in almost all PDAC cases is the 
main driver of constitutive NF-κB expression in PanINs 
and PDACs. As shown in Figure 1, the Kras mutation 
correlates with overexpression of interleukin-1α (IL-1α), 
a cytokine that binds to its receptor on the cell surface, 
through activation of AP-1. AP-1 is a transcription factor 
that is upregulated in Kras mutated cells and drives 
IL-α transcription. This leads to the polyubiquitination 
of tumor necrosis factor (TNF) receptor-associated 
factor 6 (TRAF6) at lysine 63 (K63). The K63-ubiquitin-
TRAF6 can be recognized by the K63-ubiquitin-binding 
activity of NEMO [a component of the IκB kinase (IKK) 
complex], therefore, recruiting IKK to the cellular surface. 
This binding activates the IKK complex, which then 
causes proteasomal degradation of the IκB complex via 
phosphorylation of IκB. This leads to translocation of 
NF-κB to the nucleus and activation of its target genes. 
One of its target genes is p62, an adaptor for regulating 
the turnover of K63-polyubiquitinated proteins. Thus, 
this generates an autoregulatory loop where NF-κB 
upregulates p62 expression, which in turn helps to drive 
NF-κB activity. Thus, IL-1α acts as a link between the 
Kras and NF-κB signaling pathways, which act in concert 
to drive tumor initiation and progression in PDAC [26].
In the context of Kras-induced PDAC, it has also 
been shown that NF-κB and Notch signaling interact to 
drive a sustained inflammatory response in transformed 
cells [27]. As a major transcription factor for these 
inflammatory responses, NF-κB is found to be activated 
in Kras-transformed epithelial cells [27]. Its activation 
further leads to the expression and secretion of many 
NF-κB responsive inflammatory cytokines, such as 
TNF-α. This in turn binds to its receptor to activate the 
NF-κB pathway through the IKK complex (comprising of 
IKK1, 2 and 3 subunits) via the classical NF-κB activation 
pathway. In collaboration with basal Notch signals, 
NF-κB activation induced optimal expression of Notch-
regulated genes Hes1 (hairy and enhancer of split-1) and 
Hey1 (Hairy/enhancer-of-split related with YRPW motif 
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Figure 1: A proposed working model illustrates the potential mechanism through which KrasG12D oncogenic 
signaling induces positive feedback loops of IL-1α and p62 to sustain constitutive IKKβ/NF-κB activation in PDAC 
development. KrasG12D induces the secretion of IL-1α, which further leads to the ubiquitination of TRAF6 and activation of IKKβ. 
This would further activate NF-κB to induce its target genes, including p62. The p62 protein in turn will positively regulate TRAF6 
ubiquitination and lead to the constitutive NF-κB activation and PDAC development (Adapted from Ref. 26).
protein 1). Mechanistically, TNF-α stimulation resulted 
in phosphorylation of histone H3 at the Hes1 promoter, 
and this signal was lost with Ikk2 gene deletion. Hes1 
suppresses expression of the anti-inflammatory nuclear 
receptor Pparγ (Peroxisome proliferator-activated receptor 
gamma). Thus, crosstalk between TNF-α/IKK2 and Notch 
sustains the intrinsic inflammatory profile of transformed 
cells. These findings reveal a novel interaction between 
oncogenic inflammation and a major cell fate pathway 
and show how Kras, NF-κB and Notch pathways can 
cooperate to promote cancer progression in PDAC cells.
NF-κB and cytokine/chemokine secretion 
in PDAC
In addition to its role in the Kras-induced PDAC, 
NF-κB also functions as a key link between pancreatic 
inflammation and cancer. Chronic pancreatitis is a 
chronic inflammatory condition in which the pancreas 
harbor inflammatory cells and macrophages, and exhibits 
enhanced stroma formation. During their lifetime, patients 
with chronic pancreatitis exhibit a 16-fold increased 
risk for developing PDAC [23]. One explanation for 
this increased propensity to develop PDAC is increased 
cytokine secretion from intra-pancreatic macrophages. 
Storz and colleagues showed that macrophages from 
patients with chronic pancreatitis secrete increased 
amounts of the pro-inflammatory cytokines, RANTES 
(regulated on activation normal T cell expressed and 
secreted) and TNF-α, which in turn activate NF-κB 
and promote expression of NF-κB target genes such as 
MMP-9 (Matrix metallopeptidase 9). This mechanism 
has been proposed to lead to ADM and eventually PanIN 
formation [28]. Another study has also suggested that 
transforming growth factor β (TGF-β) can activate NF-
κB to downregulate the expression of tumor suppressor 
gene Pten, thereby promoting cell motility in PDAC 
cell lines, thus suggesting that these pathways might 
get interlinked in PDAC [29]. Interestingly, the TGF-β 
activated kinase 1 (TAK1) is a key player in the activation 
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of NF-κB in many situations. For example, Shinohara 
et al [30] recently reported that the CARD-containing 
MAGUK protein 1 (CARMA1)-TAK1-IKKβ module 
is a switch mechanism for NF-κB activation in B cell 
receptor (BCR) signaling. Mutation of the scaffolding 
protein CARMA1 at serine-578, an IKKβ target, 
abrogated not only late TAK1 activity, but also the 
activation of NF-κB in B cells, suggesting the intimate 
connection between TAK1 and NF-κB activation. 
Previously, we reported that some tumor cell lines secrete 
high concentrations of TGF-β or IL-1β. We found that 
similarly high concentrations of each of these cytokines 
cross-activate the other pathway: TGF-β activates NF-κB, 
and IL-1β activates the major transcription factor Smads 
in TGF-β pathway. Importantly, TAK1 is required for this 
important cross-activation. We also found that cross-talk 
between the TGF-β and IL-1β signaling pathways leads to 
 dose-dependent cross-control of gene expression. These 
interactions provide new insight into biological responses 
to IL-1β and TGF-β in the proximity of tumors that secrete 
high concentrations of these factors and probably also at 
sites of inflammation, where the local concentrations of 
these cytokines are likely to be high [31].
In addition to cytokines, chemokines are also 
elevated in PDAC cells, and its increase is most likely 
due to enhanced NF-κB signaling. For instance, CXCL14 
is a chemokine that promotes angiogenesis and tumor 
growth and its levels are elevated in PDAC [32]. Increased 
CXCL14 levels have been shown to promote translocation 
of NF-κB to the nucleus, thus activating the NF-κB 
signaling pathway [32].
Other factors that affect NF-κB in PDAC
Besides cytokines and chemokines, NF-κB activity 
can also be affected by other factors, such as microRNAs, 
posttranslational modifications, and reactive oxygen species 
(ROS). For example, in normal cells, NF-κB repressing 
factor (Nrkf) down regulates NF-κB expression. However, 
in PDAC cells, the activity of Nrkf is down regulated by 
microRNA miR-301a, whose activity is upregulated in 
PDAC. This downregulation of Nrkf leads to the activation 
of NF-κB, which in turn promotes miR-301a transcription, 
generating a positive feedback loop to increase 
NF-κB levels. Overall, this contributes to increased tumor 
formation in mice [33].
Another characteristic observed in PDAC cell lines 
is global hyper-O-GlcNAcylation, which also relates to 
NF-κB. A recent study observed that a direct 
posttranslational O-GlcNAc modification of the NF-κB p65 
subunit and of the IKK complex promoted phosphorylation 
of p65 and nuclear localization and activation of the NF-κB 
target genes in PC cell lines [34]. Furthermore, ROS have 
been implicated in tumor development and proliferation 
in PDAC. RAGE (receptor for advanced glycation 
endproducts) is a receptor from the immunoglobulin 
superfamily involved in ROS generation. Activation of 
NF-κB leads to the upregulation of RAGE expression in 
PDAC cells [35]. Thus, NF-κB contributes to PC formation 
by ROS generation via RAGE. Moreover, the role of NF-κB 
is not only limited to PC tumor itself, it is also found to play 
a role in PC-related cachexia (or wasting syndrome) [36].
Non-classical NF-κB pathway in PC
Although the classical NF-κB pathway is the key 
contributor to PDAC development, there is increasing 
evidence that non-classical pathway also contributes 
to PDAC progression. For example, Storz’s group 
suggested that the non-classical NF-κB pathway is a 
source for the high basal NF-κB activity in PDAC cell 
lines [37]. They showed that in Panc1 and MiaPaca2 PC 
cells, increased activity of the p52/RelB NF-κB complex 
is mediated through stabilization and activation of 
NF-κB-inducing kinase (NIK). Their group identified 
proteasomal degradation of TRAF2 as a mechanism by 
which levels of active NIK are increased in PC cells. 
Such upregulation of NIK expression and activity 
levels eventually led to increased proliferation and 
anchorage-independent growth of PDAC cells [37].
Perspective
NF-κB pathway is emerging as an important player 
in PDAC. As illustrated in Figure 2, both the classical and 
non-classical arms of the pathway have been implicated 
in promoting disease progression through increased 
cancer cell proliferation, motility, anti-apoptotic and 
inflammatory signals that aid in metastasis and disease 
progression. Not only does the pathway itself contribute 
to disease initiation and progression, it gets even more 
complicated since NF-κB interacts with other pathways 
that are also deregulated in PDAC. This adds to the 
disruptions in signaling that can be seen in the different 
PDAC cases.
Numerous inhibitors of the NF-κB pathway have 
already been described, including small molecules, 
peptides, small DNA/RNA, viral proteins, natural 
compounds etc. [38]. The majority of these compounds 
have not been specifically tested in a PDAC model. 
However, it would be worth testing the efficacy of 
these compounds as a therapeutic strategy in PDAC. 
For instance, curcumin, a common cooking spice and 
resveratrol, found in red grapes and berries have been 
shown to inhibit the cytokine expression mediated by 
NF-κB [39]. Curcumin has also been shown to inhibit 
IKK activity [40]. Compounds derived from flavonoid 
precursors like chalcones, commonly found in fruits 
and vegetables were shown to decrease proliferation in 
human cancer cell lines [41]. Another flavonoid, quercetin 
interfered with cell cycle progression and induced 
apoptosis in HeLa cells by inhibiting NF-κB activity 
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[42]. Small molecule inhibitor screenings have also been 
effective in detecting compounds like N1241, which 
inhibits the ability of NF-κB to bind to DNA and interferes 
with its activity [43]. Additionally, drugs like bortezemib 
and thalidomide, which are approved by the US Food and 
Drug Administration (FDA) for the treatment of multiple 
myeloma, may also function, in part, by inhibiting NF-κB 
activity [44, 45].
Several lines of evidence have suggested that 
inhibition of NF-κB is effective in PDAC prevention 
and treatment. For instance, nitric oxide-releasing aspirin 
(NO-aspirin) represents a novel class of promising 
chemopreventive agents. Unlike conventional nonsteroidal 
anti-inflammatory drugs, NO-aspirin seems to be free of 
adverse effects while retaining the beneficial activities of 
its parent compound. Recently, Rao et al. [46] evaluated 
the effect of NO-aspirin on pancreatic carcinogenesis 
in KrasG12D mouse model. Their results revealed that 
NO-aspirin significantly suppressed pancreatic tumor 
weight, PDAC incidence, and carcinoma in situ (PanIN-3 
lesions) by decreasing ~42% the expression and activity 
of cyclooxygenase (COX), a renowned NF-κB-dependent 
gene. Later on, Streicher et al. further carried out case-
control study of aspirin use and risk of pancreatic cancer 
[47]. Moreover, since the NF-κB pathway may also 
contribute to the marked chemoresistance that occurs in 
PDAC, thus inhibiting NF-κB not only will tackle the 
problem of PDAC development and progression, but 
may also attenuate chemoresistance, thereby potentially 
improving responses to chemotherapy.
PDAC is a complex disease that is all too often 
therapy-recalcitrant. Our review suggests that combination 
therapies targeting NF-κB in conjunction with either 
classical chemotherapy, such as gemcitabine or other 
targeted therapies could yield promising therapeutic 
strategies. Direct targeting of NF-κB still faces important 
challenges due to the vital role that NF-κB plays in 
normal physiological conditions. In the future, targeting 
nonredundant cytosolic activators of NF-κB instead of 
NF-κB itself could represent a better approach to inhibit 
key processes in PC. In this regard, it makes the discovery 
of pathway-specific novel activators of NF-κB a very 
Figure 2: Interactions of NF-κB signaling pathway in pancreatic cancer (PC). As indicated in the diagram, both classical and 
non-classical NF-κB pathways interact with a number of signaling pathways to remain constitutively activated in pancreatic cancer cells 
and promotes tumorigenesis and metastasis.
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attractive task [48, 49] for drug target identification and 
PDAC treatment.
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